TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01924572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord clamping at 2 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord clamping at 5 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord milking
Study: NCT02586909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 35 mg tablets
Description: once daily, oral tablets
Study: NCT01456598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: * After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: * After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance.
Study: NCT01778296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the neurocutaneous island flap
Description: The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
Study: NCT01613066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone Allogeneic Transplant
Description: Unrelated single unit intrabone cord blood transplantation
Study: NCT03992456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT01832896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide subcutaneous dosing
Description: For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
Study: NCT03953391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
Study: NCT03253809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Vision Guidewire
Description: The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
Study: NCT02943369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Description: Ticagrelor 180 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180 mg loading dose
Description: Ticagrelor 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min
Description: Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
Study: NCT00326339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R788
Description: R788 50 mg, 100 mg, or 150 mg PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R788
Description: R788 50 mg, 100 mg, or 150 mg PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R788
Description: R788 50 mg, 100 mg, or 150 mg PO bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO bid
Study: NCT03672201

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Pharmacological Intervention
Description: The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Intervention
Description: The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
Study: NCT02187406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified ankle athletic taping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional ankle athletic taping
Study: NCT02238639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).
Description: If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation.
Study: NCT01231880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four monthly IPT with dihydroartemisinin Piperaquine (DP)
Description: Given every 4 months (once a school term)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly IPT using DP
Description: Given every month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo given every month
Description: No active ingredient
Study: NCT04162301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3002
Description: CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
Study: NCT04240665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Memory Notebook (DMN) Application
Description: Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
Study: NCT01771627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Study: NCT03022799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04074109

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Teleyoga
Description: the yoga protocol will be delivered via a tablet computer to groups of participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person yoga
Description: the yoga protocol will be delivered by a yoga instructor in the room to group of participants
Study: NCT04613310

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid Diagnostic Test vs PCR
Description: 4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
Study: NCT03185949

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endobar Infusion Catheter System
Description: Bariatric embolization with microspheres using Endobar Infusion Catheter System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobar Infusion Catheter System
Description: Bariatric embolization with microspheres using Endobar Infusion Catheter System

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral therapy
Description: Healthy diet and exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: Healthy diet and exercise
Study: NCT02701049

Intervention type: OTHER
Group type: OTHER
Intervention: Methods to collect SO/GI information in the ED
Description: In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
Study: NCT03889405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVU™
Description: The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUPC
Description: The study participants will undergo continuous recording of the uterine contractions by IUPC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOCO
Description: Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
Study: NCT02388659

Intervention type: DEVICE
Intervention: 3 Tesla scanning
Description: Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
Study: NCT01830257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sending message
Description: Sending the suggestive short message
Study: NCT04905238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure
Study: NCT02149277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgrastim
Description: The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
Study: NCT00672308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber with ORS
Description: Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber with ORS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber with ORS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the reduced-osmolarity WHO-ORS without added Benefiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the reduced-osmolarity WHO-ORS without added Benefiber
Study: NCT00658086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-RSV01
Description: administered by nebulization once daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: administered by nebulization once daily for 3 days
Study: NCT01004575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantation of Kaname Cobalt-Chromium coronary stent
Description: implantation of Kaname Cobalt-Chromium coronary stent
Study: NCT00057330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine
Description: the vaccine was administered intramuscularly in the non-dominant deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Description: the vaccine was administered intramuscularly in the non-dominant deltoid
Study: NCT03009591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver.
Study: NCT03145038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed
Description: Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted
Description: Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed
Description: Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast
Description: 10 mg IR tablet, intact (fed; American breakfast)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast
Description: 10 mg IR tablet, crushed (fed; American breakfast)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast
Description: 10 mg IR tablet, intact (fed; Continental breakfast)
Study: NCT00094900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1 Trap
Study: NCT00817427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controls Short sleep
Description: Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CKD- sleep extension
Description: Sleep will be increased by 2 hours each night for 3 nights
Study: NCT03801200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: radiotherapy with Apatinib
Study: NCT04330677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of 24 International Units, Oxytocin will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Gel
Description: Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Gel
Description: Participants received a single dose of estradiol gel (Estramon 2 mg estradiol, Hexal AG, Holzkirchen, Germany), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel
Description: Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study: NCT02724215

Intervention type: DEVICE
Intervention: Sleep Apnea Screening (Out of Center Polysomnography Device)

Intervention type: DEVICE
Intervention: Sleep Apnea Screening (Out of Center Polysomnography Device)
Study: NCT01436942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes.
Study: NCT00960232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 40.000 IU cholecalciferol per week for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00407966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study: NCT00218023

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
Study: NCT00407966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study: NCT00218023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
Study: NCT04607265

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Comparison of scar characteristics on cardiac MRI between the two groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Comparison of scar characteristics on cardiac MRI between the two groups.
Study: NCT04038307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1gm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 100ml
Study: NCT01615900

Intervention type: OTHER
Group type: OTHER
Intervention: Teleconsultation / Standard consultation
Description: Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)

Intervention type: OTHER
Group type: OTHER
Intervention: Teleconsultation / Standard consultation
Description: Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~* Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~* Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~* Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~* Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)